GRAPPA-OMERACT consensus-based recommendations and research agenda for use of composite measures and treatment targets in PsA

Laura C Coates, Oliver Fitzgerald, Joseph F Merola, Josef Smolen, Leonieke J J van Mens, Heidi Bertheussen, Wolf-Henning Boehncke, Kristina Callis Duffin, Willemina Campbell, Maarten de Wit, Dafna D Gladman, Alice Gottlieb, Jana James, Arthur F Kavanaugh, Lars Erik Kristensen, Tore K Kvien, Thomas Luger, Neil McHugh, Philip J Mease, Peter Nash & 6 others Alexis Ogdie, Cheryl F Rosen, Vibeke Strand, William Tillett, Douglas J Veale, Philip S Helliwell

Research output: Contribution to journalArticle

14 Citations (Scopus)
14 Downloads (Pure)

Abstract

BACKGROUND: Many composite disease activity measures and targets have been developed for psoriatic arthritis (PsA). This GRAPPA-OMERACT work stream aimed to further the development of consensus among physicians and patients.

METHODS: Prior to the meeting, physicians and patients were surveyed on outcome measures. A consensus meeting (26 rheumatologists, dermatologists, and patient representatives) reviewed evidence on composite measures and potential treatment targets, plus survey results. After discussions, participants voted on proposals for use and consensus was established in a second survey.

RESULTS: Survey results from 128 HCPS and 139 patients were analysed alongside a SLR summarising evidence. A weighted vote was cast for composite measures (for RCTs, most popular measures were PASDAS [40 votes] and GRACE [28 votes]; for clinical practice, most popular were 3-VAS [45 votes], DAPSA [26 votes]). After discussion there was no consensus on a composite measure. The group agreed that several composite measures could be used. Future studies should allow further validation and comparison. The group unanimously agreed that remission should be the ideal target with minimal/low disease activity a feasible alternative. The target should include assessment of musculoskeletal disease, skin and health related quality of life. The group recommended a target of treatment as VLDA, or MDA.

CONCLUSIONS: Consensus was not reached on a continuous measure of disease activity. In the interim the group recommends several composites. Consensus was reached on a treatment target of VLDA/MDA. An extensive research agenda was composed and recommends that data on all PsA clinical domains be collected in ongoing studies. This article is protected by copyright. All rights reserved.

Original languageEnglish
Pages (from-to)345-355
JournalArthritis & Rheumatology
Volume70
Issue number3
Early online date28 Nov 2017
DOIs
Publication statusPublished - 31 Mar 2018

Fingerprint

Psoriatic Arthritis
Consensus
Research
Therapeutics
Musculoskeletal Diseases
Physicians
Patient Advocacy
Quality of Life
Outcome Assessment (Health Care)
Skin
Surveys and Questionnaires

Keywords

  • Journal Article

Cite this

Coates, L. C., Fitzgerald, O., Merola, J. F., Smolen, J., van Mens, L. J. J., Bertheussen, H., ... Helliwell, P. S. (2018). GRAPPA-OMERACT consensus-based recommendations and research agenda for use of composite measures and treatment targets in PsA. Arthritis & Rheumatology, 70(3), 345-355. https://doi.org/10.1002/art.40391

GRAPPA-OMERACT consensus-based recommendations and research agenda for use of composite measures and treatment targets in PsA. / Coates, Laura C; Fitzgerald, Oliver; Merola, Joseph F; Smolen, Josef; van Mens, Leonieke J J; Bertheussen, Heidi; Boehncke, Wolf-Henning; Callis Duffin, Kristina; Campbell, Willemina; de Wit, Maarten; Gladman, Dafna D; Gottlieb, Alice; James, Jana; Kavanaugh, Arthur F; Kristensen, Lars Erik; Kvien, Tore K; Luger, Thomas; McHugh, Neil; Mease, Philip J; Nash, Peter; Ogdie, Alexis; Rosen, Cheryl F; Strand, Vibeke; Tillett, William; Veale, Douglas J; Helliwell, Philip S.

In: Arthritis & Rheumatology, Vol. 70, No. 3, 31.03.2018, p. 345-355.

Research output: Contribution to journalArticle

Coates, LC, Fitzgerald, O, Merola, JF, Smolen, J, van Mens, LJJ, Bertheussen, H, Boehncke, W-H, Callis Duffin, K, Campbell, W, de Wit, M, Gladman, DD, Gottlieb, A, James, J, Kavanaugh, AF, Kristensen, LE, Kvien, TK, Luger, T, McHugh, N, Mease, PJ, Nash, P, Ogdie, A, Rosen, CF, Strand, V, Tillett, W, Veale, DJ & Helliwell, PS 2018, 'GRAPPA-OMERACT consensus-based recommendations and research agenda for use of composite measures and treatment targets in PsA', Arthritis & Rheumatology, vol. 70, no. 3, pp. 345-355. https://doi.org/10.1002/art.40391
Coates, Laura C ; Fitzgerald, Oliver ; Merola, Joseph F ; Smolen, Josef ; van Mens, Leonieke J J ; Bertheussen, Heidi ; Boehncke, Wolf-Henning ; Callis Duffin, Kristina ; Campbell, Willemina ; de Wit, Maarten ; Gladman, Dafna D ; Gottlieb, Alice ; James, Jana ; Kavanaugh, Arthur F ; Kristensen, Lars Erik ; Kvien, Tore K ; Luger, Thomas ; McHugh, Neil ; Mease, Philip J ; Nash, Peter ; Ogdie, Alexis ; Rosen, Cheryl F ; Strand, Vibeke ; Tillett, William ; Veale, Douglas J ; Helliwell, Philip S. / GRAPPA-OMERACT consensus-based recommendations and research agenda for use of composite measures and treatment targets in PsA. In: Arthritis & Rheumatology. 2018 ; Vol. 70, No. 3. pp. 345-355.
@article{16f4f21f7a9647c19fe6d1bbbc55742b,
title = "GRAPPA-OMERACT consensus-based recommendations and research agenda for use of composite measures and treatment targets in PsA",
abstract = "BACKGROUND: Many composite disease activity measures and targets have been developed for psoriatic arthritis (PsA). This GRAPPA-OMERACT work stream aimed to further the development of consensus among physicians and patients.METHODS: Prior to the meeting, physicians and patients were surveyed on outcome measures. A consensus meeting (26 rheumatologists, dermatologists, and patient representatives) reviewed evidence on composite measures and potential treatment targets, plus survey results. After discussions, participants voted on proposals for use and consensus was established in a second survey.RESULTS: Survey results from 128 HCPS and 139 patients were analysed alongside a SLR summarising evidence. A weighted vote was cast for composite measures (for RCTs, most popular measures were PASDAS [40 votes] and GRACE [28 votes]; for clinical practice, most popular were 3-VAS [45 votes], DAPSA [26 votes]). After discussion there was no consensus on a composite measure. The group agreed that several composite measures could be used. Future studies should allow further validation and comparison. The group unanimously agreed that remission should be the ideal target with minimal/low disease activity a feasible alternative. The target should include assessment of musculoskeletal disease, skin and health related quality of life. The group recommended a target of treatment as VLDA, or MDA.CONCLUSIONS: Consensus was not reached on a continuous measure of disease activity. In the interim the group recommends several composites. Consensus was reached on a treatment target of VLDA/MDA. An extensive research agenda was composed and recommends that data on all PsA clinical domains be collected in ongoing studies. This article is protected by copyright. All rights reserved.",
keywords = "Journal Article",
author = "Coates, {Laura C} and Oliver Fitzgerald and Merola, {Joseph F} and Josef Smolen and {van Mens}, {Leonieke J J} and Heidi Bertheussen and Wolf-Henning Boehncke and {Callis Duffin}, Kristina and Willemina Campbell and {de Wit}, Maarten and Gladman, {Dafna D} and Alice Gottlieb and Jana James and Kavanaugh, {Arthur F} and Kristensen, {Lars Erik} and Kvien, {Tore K} and Thomas Luger and Neil McHugh and Mease, {Philip J} and Peter Nash and Alexis Ogdie and Rosen, {Cheryl F} and Vibeke Strand and William Tillett and Veale, {Douglas J} and Helliwell, {Philip S}",
note = "This article is protected by copyright. All rights reserved.",
year = "2018",
month = "3",
day = "31",
doi = "10.1002/art.40391",
language = "English",
volume = "70",
pages = "345--355",
journal = "Arthritis & Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - GRAPPA-OMERACT consensus-based recommendations and research agenda for use of composite measures and treatment targets in PsA

AU - Coates, Laura C

AU - Fitzgerald, Oliver

AU - Merola, Joseph F

AU - Smolen, Josef

AU - van Mens, Leonieke J J

AU - Bertheussen, Heidi

AU - Boehncke, Wolf-Henning

AU - Callis Duffin, Kristina

AU - Campbell, Willemina

AU - de Wit, Maarten

AU - Gladman, Dafna D

AU - Gottlieb, Alice

AU - James, Jana

AU - Kavanaugh, Arthur F

AU - Kristensen, Lars Erik

AU - Kvien, Tore K

AU - Luger, Thomas

AU - McHugh, Neil

AU - Mease, Philip J

AU - Nash, Peter

AU - Ogdie, Alexis

AU - Rosen, Cheryl F

AU - Strand, Vibeke

AU - Tillett, William

AU - Veale, Douglas J

AU - Helliwell, Philip S

N1 - This article is protected by copyright. All rights reserved.

PY - 2018/3/31

Y1 - 2018/3/31

N2 - BACKGROUND: Many composite disease activity measures and targets have been developed for psoriatic arthritis (PsA). This GRAPPA-OMERACT work stream aimed to further the development of consensus among physicians and patients.METHODS: Prior to the meeting, physicians and patients were surveyed on outcome measures. A consensus meeting (26 rheumatologists, dermatologists, and patient representatives) reviewed evidence on composite measures and potential treatment targets, plus survey results. After discussions, participants voted on proposals for use and consensus was established in a second survey.RESULTS: Survey results from 128 HCPS and 139 patients were analysed alongside a SLR summarising evidence. A weighted vote was cast for composite measures (for RCTs, most popular measures were PASDAS [40 votes] and GRACE [28 votes]; for clinical practice, most popular were 3-VAS [45 votes], DAPSA [26 votes]). After discussion there was no consensus on a composite measure. The group agreed that several composite measures could be used. Future studies should allow further validation and comparison. The group unanimously agreed that remission should be the ideal target with minimal/low disease activity a feasible alternative. The target should include assessment of musculoskeletal disease, skin and health related quality of life. The group recommended a target of treatment as VLDA, or MDA.CONCLUSIONS: Consensus was not reached on a continuous measure of disease activity. In the interim the group recommends several composites. Consensus was reached on a treatment target of VLDA/MDA. An extensive research agenda was composed and recommends that data on all PsA clinical domains be collected in ongoing studies. This article is protected by copyright. All rights reserved.

AB - BACKGROUND: Many composite disease activity measures and targets have been developed for psoriatic arthritis (PsA). This GRAPPA-OMERACT work stream aimed to further the development of consensus among physicians and patients.METHODS: Prior to the meeting, physicians and patients were surveyed on outcome measures. A consensus meeting (26 rheumatologists, dermatologists, and patient representatives) reviewed evidence on composite measures and potential treatment targets, plus survey results. After discussions, participants voted on proposals for use and consensus was established in a second survey.RESULTS: Survey results from 128 HCPS and 139 patients were analysed alongside a SLR summarising evidence. A weighted vote was cast for composite measures (for RCTs, most popular measures were PASDAS [40 votes] and GRACE [28 votes]; for clinical practice, most popular were 3-VAS [45 votes], DAPSA [26 votes]). After discussion there was no consensus on a composite measure. The group agreed that several composite measures could be used. Future studies should allow further validation and comparison. The group unanimously agreed that remission should be the ideal target with minimal/low disease activity a feasible alternative. The target should include assessment of musculoskeletal disease, skin and health related quality of life. The group recommended a target of treatment as VLDA, or MDA.CONCLUSIONS: Consensus was not reached on a continuous measure of disease activity. In the interim the group recommends several composites. Consensus was reached on a treatment target of VLDA/MDA. An extensive research agenda was composed and recommends that data on all PsA clinical domains be collected in ongoing studies. This article is protected by copyright. All rights reserved.

KW - Journal Article

U2 - 10.1002/art.40391

DO - 10.1002/art.40391

M3 - Article

VL - 70

SP - 345

EP - 355

JO - Arthritis & Rheumatology

JF - Arthritis & Rheumatology

SN - 2326-5191

IS - 3

ER -